Navigation Links
Stopping a cancer trial early: is it for the benefit of patients or industry?
Date:4/8/2008

New research has identified a growing trend for trials of new cancer treatments to be stopped prematurely before the therapies risks and benefits have been properly evaluated.

In a study, published online today (Wednesday 9 April) in the cancer journal, Annals of Oncology [1], Italian researchers analysed 25 randomised controlled clinical trials that had been stopped early because they had started to show a benefit to patients and found that the numbers had increased dramatically in recent years. They warn that this could lead to a systematic over-statement of the effects of treatment, and that patients could be harmed by new therapies being rushed prematurely into the clinic.

Out of 14 trials stopped because they started to show benefit to patients and published between 2005-2007, the researchers found that 11 (79%) were used to support an application for marketing authorisation at the European Medicines Agency (EMEA) and the United States Food and Drug Administration (FDA).

This suggests a commercial component in stopping trials prematurely. In fact, this strategy (i.e. stopping trials early for benefit) could guarantee quicker access to the market for companies. On the other hand, a quicker clinical drug development may lead to an immature benefit/risk balance of new drugs, Dr Giovanni Apolone, one of the authors, told a news briefing yesterday (Tuesday).

Dr Apolone, head of the Laboratory of Translational and Outcome Research in Oncology, Mario Negri Institute for Pharmacological Research, Milan, Italy, continued: When we analysed 25 trials over a ten year period between 1997 and 2007, we found a consistent increase in prematurely stopped trials more than 50% were stopped within the last three years.

We are aware that trials stopped early because they are showing benefit may result in the identification of promising new treatments for patients. However, findings obtained following this strategy should be considered to be preliminary results that require subsequent confirmation. We believe that only untruncated trials can provide the full level of evidence required to safely translate treatments into clinical practice. Without such evidence, unsafe and ineffective drugs could be marketed and prescribed, and patients health could be jeopardised.

He pointed out that it can take several years for the long-term benefits or adverse side-effects of a treatment to become apparent, but the average study duration was 30 months among the 25 trials they analysed (with a range of between 12 and 64 months).

In their paper the authors write: If a trial is evaluating the long-term efficacy of a treatment of conditions such as cancer, short-term benefits, no matter how significant statistically, may not justify early stopping. Data on disease recurrence and progression, drug resistance, metastasis, or adverse events, all factors that weight heavily in the benefit/risk balance, could easily be missed.

An early stop may reduce the likelihood of detecting a difference in overall survival (the only relevant end point in this setting) because of the small sample, the possibility of crossing-over the experimental drugs, and contamination with other treatments.

The authors said they were particularly concerned that, by the time they were stopped, five studies had enrolled less than 40% of the total number of patients planned for final analysis. It is obvious that the risk of overestimating treatment effects increases markedly when the sample is small, they write.

Dr Apolone said: We believe that, in general and unless harm is being shown, cancer trials should be completed so that the correct number of patients over the correct period of time required for a significant final analysis can be recruited. Our study describes a growing phenomenon of trials stopped prematurely, which is now the subject of debate within the international scientific community.

Professor David Kerr, the editor in chief of Annals of Oncology, told the news briefing: We, as scientists, put a great deal of work and effort into designing appropriate clinical trials, and in all but the rarest of cases we should not rush to abandon those designs in the face of early signs of benefit. Moreover, as researchers we make an ethical commitment to patients entering studies to do the research as designed and presented to those patients. Everyone wants new and powerful therapies available quickly in clinic, but we all, patients perhaps most of all, recognise the need for good science and strong ethics.

Professor Stuart Pocock, Professor of Medical Statistics at the London School of Hygiene and Tropical Medicine (UK), who was not involved in the study, told the news briefing: Clinical trials need to stop early for superior benefit whenever theres proof beyond reasonable doubt that the new treatment really is superior. That would be an ethical obligation. However, too many trials are stopped early claiming efficacy without such strong evidence being available.


'/>"/>

Contact: Emma Mason
wordmason@mac.com
07-711-296-986
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. Stopping a deadly killer
2. Stopping a receptor called nogo boosts the synapses
3. Fugitive cancer cells can be blocked by stopping blood cells that aid them
4. Physicians focus on stopping pain epidemic
5. First 90 Days After Stopping Plavix Most Dangerous
6. New Booklet Reveals 12 Proven Methods for Stopping MRSA from Infecting Your Feet and Your Familys Feet
7. New Sedona Stopping Diabetes Program
8. Common drug for stopping preterm labor may be harmful for babies
9. Hands2GO(R) Hand Sanitizer Offers Alcohol-Free Alternative to Stopping the Spread of Flu at School and Work
10. On 30th Anniversary, Angioplasty Celebrated as Modern Medical Breakthrough in Stopping Heart Attack
11. Stopping Tysabri May Worsen MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology: